Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects

NCT02275065 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02275065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02275065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Completed
Start date
October 24, 2014
Completion date
January 29, 2015
Enrollment
23 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1 infection